Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.41 |
| ▸ | SYK | P43405 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | ILK | Q13418 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22256141 | 0.93 | TLR8 (0.38) | TLR8TLR7SYKKCNH2AURKB | |
| SCHEMBL22234274 | 0.84 | NLRP3 (0.47) | SYKKCNH2ILKPRKCAPRKCD | |
| SCHEMBL22234415 | 0.81 | ILK (0.37) | TLR8TLR7SYKAURKBILK | |
| SCHEMBL30930059 | 0.81 | ILK (0.37) | TLR8TLR7SYKAURKBILK | |
| SCHEMBL22256210 | 0.81 | PGK1 (0.41) | TLR8TLR7KCNH2NLRP3CYP1A2 | |
| SCHEMBL22256209 | 0.80 | APP (0.36) | TLR8TLR7NLRP3 | |
| SCHEMBL22256177 | 0.80 | NLRP3 (0.53) | TLR8TLR7SYKKCNH2AURKB | |
| SCHEMBL22234422 | 0.80 | ILK (0.38) | TLR8TLR7SYKKCNH2AURKB | |
| SCHEMBL22234173 | 0.80 | TLR8 (0.37) | TLR8TLR7SYKKCNH2ILK | |
| SCHEMBL22234168 | 0.80 | ILK (0.39) | TLR8TLR7SYKAURKBILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087991-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2020150114-A1 | HETEROCYCLIC NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087991-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | TLR8 210/4885TLR7 236/4885SYK 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.